Tullio Pozzan Selected Research

Presenilin-2

6/2021	Familial Alzheimer's disease presenilin-2 mutants affect Ca2+ homeostasis and brain network excitability.
1/2021	Calcium Signaling and Mitochondrial Function in Presenilin 2 Knock-Out Mice: Looking for Any Loss-of-Function Phenotype Related to Alzheimer's Disease.
1/2020	Intracellular Calcium Dysregulation by the Alzheimer's Disease-Linked Protein Presenilin 2.
1/2020	Presenilin-2 and Calcium Handling: Molecules, Organelles, Cells and Brain Networks.
9/2016	Characterization of the ER-Targeted Low Affinity Ca(2+) Probe D4ER.
1/2016	Presenilin 2 Modulates Endoplasmic Reticulum-Mitochondria Coupling by Tuning the Antagonistic Effect of Mitofusin 2.
10/2012	Ca2+ dysregulation in neurons from transgenic mice expressing mutant presenilin 2.
9/2009	Presenilin-2 dampens intracellular Ca2+ stores by increasing Ca2+ leakage and reducing Ca2+ uptake.
4/2005	Reduction of Ca2+ stores and capacitative Ca2+ entry is associated with the familial Alzheimer's disease presenilin-2 T122R mutation and anticipates the onset of dementia.
3/2004	The presenilin 2 M239I mutation associated with familial Alzheimer's disease reduces Ca2+ release from intracellular stores.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tullio Pozzan Research Topics

Disease

18	Alzheimer Disease (Alzheimer's Disease) 10/2021 - 03/2004
3	Hypertrophy 10/2017 - 02/2008
2	Amyloid Plaque 01/2021 - 07/2020
2	Neoplasms (Cancer) 11/2015 - 07/2009
2	Inborn Genetic Diseases (Disease, Hereditary) 07/2005 - 06/2003
2	Skin Diseases (Skin Disease) 10/2003 - 10/2003
2	Benign Familial Pemphigus (Hailey Hailey Disease) 10/2003 - 10/2003
1	Neuroblastoma 01/2019
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018
1	Parasitemia 01/2017
1	Memory Disorders (Memory Loss) 02/2015
1	Polycystic liver disease 03/2012
1	Cysts 03/2012
1	Epilepsy (Aura) 04/2010
1	Seizures (Absence Seizure) 04/2010
1	Partial Epilepsies (Epilepsy, Partial) 04/2010
1	Cystic Fibrosis (Mucoviscidosis) 07/2005
1	Liver Diseases (Liver Disease) 07/2005
1	Dementia (Dementias) 04/2005
1	Deafness (Deaf Mutism) 01/2005
1	Malaria 04/2003
1	Mitochondrial Diseases (Mitochondrial Disease) 04/2003

Drug/Important Bio-Agent (IBA)

10	Presenilin-2IBA 06/2021 - 03/2004
8	Proteins (Proteins, Gene)FDA Link 07/2020 - 04/2003
8	Flavin-Adenine Dinucleotide (FAD)IBA 01/2020 - 03/2004
5	PresenilinsIBA 01/2019 - 03/2004
4	Amyloid (Amyloid Fibrils)IBA 07/2020 - 10/2012
3	Presenilin-1IBA 01/2021 - 09/2009
3	CalciumIBA 01/2020 - 04/2003
2	Peptides (Polypeptides)IBA 01/2021 - 02/2015
2	Amyloid beta-PeptidesIBA 01/2021 - 07/2020
2	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 01/2021 - 07/2020
2	CalcineurinIBA 03/2008 - 02/2008
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 03/2008 - 02/2008
2	Calcium-Transporting ATPases (Ca2+ ATPase)IBA 10/2003 - 10/2003
1	NAD (NADH)IBA 01/2018
1	A-factor (Streptomyces)IBA 10/2017
1	mitochondrial calcium uniporterIBA 10/2017
1	Nitroprusside (Sodium Nitroprusside)FDA LinkGeneric 01/2017
1	Nitric Oxide DonorsIBA 01/2017
1	Transcription Factors (Transcription Factor)IBA 11/2015
1	TOR Serine-Threonine KinasesIBA 03/2012
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 03/2012
1	TRPP Cation ChannelsIBA 03/2012
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 03/2012
1	1-dodecylpyridoxal (PLD)IBA 03/2012
1	N-Methylaspartate (NMDA)IBA 04/2010
1	Pharmaceutical PreparationsIBA 04/2010
1	Vitamin K 3 (Menadione)FDA Link 07/2009
1	Calcineurin InhibitorsIBA 02/2008
1	Glyburide (Glibenclamide)FDA LinkGeneric 07/2005
1	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 07/2005
1	Adenosine (Adenocard)FDA LinkGeneric 07/2005
1	ConnexinsIBA 01/2005
1	Connexin 26IBA 01/2005

Therapy/Procedure

2	Therapeutics 10/2021 - 04/2010